Molecular targeted cancer therapy mediated by nanoparticles (NPs) is a promising strategy to overcome the lack of specificity of conventional chemotherapeutic agents. In this context, the prostate-specific membrane antigen (PSMA) has demonstrated a powerful potential for the management of prostate cancer (PCa). Cancer chemoprevention by phytochemicals is emerging as a suitable approach for the treatment of early carcinogenic processes. Since (-)-epigallocatechin 3-gallate (EGCG) has shown potent chemopreventive efficacy for PCa, we designed and developed novel targeted NPs in order to selectively deliver EGCG to cancer cells. Herein, to explore the recent concept of "nanochemoprevention", we present a study on EGCG-loaded NPs consisting of biocompatible polymers, functionalized with small molecules targeting PSMA, that exhibited a selective in vitro efficacy against PSMA-expressing PCa cells. This approach could be beneficial for high risk patients and would fulfill a significant therapeutic need, thus opening new perspectives for novel and effective treatment for PCa. © 2011 American Chemical Society.

Targeted Biocompatible Nanoparticles for tie Delivery of (-)-Epigallocatechin 3-Gallate to Prostate Cancer Cells / Sanna, V; Pintus, Gianfranco; Roggio, Am; Punzoni, S; Posadino, Am; Arca, A; Marceddu, S; Bandiera, Pasquale; Uzzau, Sergio; Sechi, M.. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 54:5(2011), pp. 1321-1332. (Intervento presentato al convegno “Nanodrug delivery: from the bench to the patient” tenutosi a Rome, Italy nel October 10-13) [10.1021/jm1013715].

Targeted Biocompatible Nanoparticles for tie Delivery of (-)-Epigallocatechin 3-Gallate to Prostate Cancer Cells

PINTUS, Gianfranco;Posadino AM;BANDIERA, Pasquale;UZZAU, Sergio;Sechi M.
2011-01-01

Abstract

Molecular targeted cancer therapy mediated by nanoparticles (NPs) is a promising strategy to overcome the lack of specificity of conventional chemotherapeutic agents. In this context, the prostate-specific membrane antigen (PSMA) has demonstrated a powerful potential for the management of prostate cancer (PCa). Cancer chemoprevention by phytochemicals is emerging as a suitable approach for the treatment of early carcinogenic processes. Since (-)-epigallocatechin 3-gallate (EGCG) has shown potent chemopreventive efficacy for PCa, we designed and developed novel targeted NPs in order to selectively deliver EGCG to cancer cells. Herein, to explore the recent concept of "nanochemoprevention", we present a study on EGCG-loaded NPs consisting of biocompatible polymers, functionalized with small molecules targeting PSMA, that exhibited a selective in vitro efficacy against PSMA-expressing PCa cells. This approach could be beneficial for high risk patients and would fulfill a significant therapeutic need, thus opening new perspectives for novel and effective treatment for PCa. © 2011 American Chemical Society.
2011
Targeted Biocompatible Nanoparticles for tie Delivery of (-)-Epigallocatechin 3-Gallate to Prostate Cancer Cells / Sanna, V; Pintus, Gianfranco; Roggio, Am; Punzoni, S; Posadino, Am; Arca, A; Marceddu, S; Bandiera, Pasquale; Uzzau, Sergio; Sechi, M.. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 54:5(2011), pp. 1321-1332. (Intervento presentato al convegno “Nanodrug delivery: from the bench to the patient” tenutosi a Rome, Italy nel October 10-13) [10.1021/jm1013715].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/155987
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 132
  • ???jsp.display-item.citation.isi??? 19
social impact